List of Tables
Table 1. Global Moderate to Severe Plaque Psoriasis Medications Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Moderate to Severe Plaque Psoriasis Medications Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Moderate to Severe Plaque Psoriasis Medications Market Competitive Situation by Manufacturers in 2024
Table 4. Global Moderate to Severe Plaque Psoriasis Medications Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Moderate to Severe Plaque Psoriasis Medications Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Moderate to Severe Plaque Psoriasis Medications Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Moderate to Severe Plaque Psoriasis Medications Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Moderate to Severe Plaque Psoriasis Medications, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Moderate to Severe Plaque Psoriasis Medications, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Moderate to Severe Plaque Psoriasis Medications, Product Type & Application
Table 12. Global Key Manufacturers of Moderate to Severe Plaque Psoriasis Medications, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Moderate to Severe Plaque Psoriasis Medications by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Moderate to Severe Plaque Psoriasis Medications as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Moderate to Severe Plaque Psoriasis Medications Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Moderate to Severe Plaque Psoriasis Medications Sales by Region (2020-2025) & (K Units)
Table 18. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Region (2020-2025)
Table 19. Global Moderate to Severe Plaque Psoriasis Medications Sales by Region (2026-2031) & (K Units)
Table 20. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Region (2026-2031)
Table 21. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Region (2020-2025)
Table 23. Global Moderate to Severe Plaque Psoriasis Medications Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Region (2026-2031)
Table 25. North America Moderate to Severe Plaque Psoriasis Medications Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Moderate to Severe Plaque Psoriasis Medications Sales by Country (2020-2025) & (K Units)
Table 27. North America Moderate to Severe Plaque Psoriasis Medications Sales by Country (2026-2031) & (K Units)
Table 28. North America Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Moderate to Severe Plaque Psoriasis Medications Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Moderate to Severe Plaque Psoriasis Medications Sales by Country (2020-2025) & (K Units)
Table 32. Europe Moderate to Severe Plaque Psoriasis Medications Sales by Country (2026-2031) & (K Units)
Table 33. Europe Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Moderate to Severe Plaque Psoriasis Medications Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Moderate to Severe Plaque Psoriasis Medications Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Moderate to Severe Plaque Psoriasis Medications Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Moderate to Severe Plaque Psoriasis Medications Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Moderate to Severe Plaque Psoriasis Medications Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Moderate to Severe Plaque Psoriasis Medications Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Moderate to Severe Plaque Psoriasis Medications Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Moderate to Severe Plaque Psoriasis Medications Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Moderate to Severe Plaque Psoriasis Medications Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Moderate to Severe Plaque Psoriasis Medications Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Moderate to Severe Plaque Psoriasis Medications Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Moderate to Severe Plaque Psoriasis Medications Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Moderate to Severe Plaque Psoriasis Medications Sales (K Units) by Type (2020-2025)
Table 51. Global Moderate to Severe Plaque Psoriasis Medications Sales (K Units) by Type (2026-2031)
Table 52. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2020-2025)
Table 53. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Type (2026-2031)
Table 54. Global Moderate to Severe Plaque Psoriasis Medications Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Moderate to Severe Plaque Psoriasis Medications Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Type (2020-2025)
Table 57. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Type (2026-2031)
Table 58. Global Moderate to Severe Plaque Psoriasis Medications Price (US$/Unit) by Type (2020-2025)
Table 59. Global Moderate to Severe Plaque Psoriasis Medications Price (US$/Unit) by Type (2026-2031)
Table 60. Global Moderate to Severe Plaque Psoriasis Medications Sales (K Units) by Application (2020-2025)
Table 61. Global Moderate to Severe Plaque Psoriasis Medications Sales (K Units) by Application (2026-2031)
Table 62. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Application (2020-2025)
Table 63. Global Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Application (2026-2031)
Table 64. Global Moderate to Severe Plaque Psoriasis Medications Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Moderate to Severe Plaque Psoriasis Medications Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Application (2020-2025)
Table 67. Global Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Application (2026-2031)
Table 68. Global Moderate to Severe Plaque Psoriasis Medications Price (US$/Unit) by Application (2020-2025)
Table 69. Global Moderate to Severe Plaque Psoriasis Medications Price (US$/Unit) by Application (2026-2031)
Table 70. Janssen Biotech Company Information
Table 71. Janssen Biotech Description and Business Overview
Table 72. Janssen Biotech Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Janssen Biotech Moderate to Severe Plaque Psoriasis Medications Product
Table 74. Janssen Biotech Recent Developments/Updates
Table 75. Abbvie Company Information
Table 76. Abbvie Description and Business Overview
Table 77. Abbvie Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Abbvie Moderate to Severe Plaque Psoriasis Medications Product
Table 79. Abbvie Recent Developments/Updates
Table 80. Sandoz Company Information
Table 81. Sandoz Description and Business Overview
Table 82. Sandoz Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Sandoz Moderate to Severe Plaque Psoriasis Medications Product
Table 84. Sandoz Recent Developments/Updates
Table 85. Amgen Company Information
Table 86. Amgen Description and Business Overview
Table 87. Amgen Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Amgen Moderate to Severe Plaque Psoriasis Medications Product
Table 89. Amgen Recent Developments/Updates
Table 90. Eli Lilly Company Information
Table 91. Eli Lilly Description and Business Overview
Table 92. Eli Lilly Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Eli Lilly Moderate to Severe Plaque Psoriasis Medications Product
Table 94. Eli Lilly Recent Developments/Updates
Table 95. Novartis Company Information
Table 96. Novartis Description and Business Overview
Table 97. Novartis Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Novartis Moderate to Severe Plaque Psoriasis Medications Product
Table 99. Novartis Recent Developments/Updates
Table 100. Sun Pharmaceutical Industries Company Information
Table 101. Sun Pharmaceutical Industries Description and Business Overview
Table 102. Sun Pharmaceutical Industries Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Sun Pharmaceutical Industries Moderate to Severe Plaque Psoriasis Medications Product
Table 104. Sun Pharmaceutical Industries Recent Developments/Updates
Table 105. UCB, Inc Company Information
Table 106. UCB, Inc Description and Business Overview
Table 107. UCB, Inc Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. UCB, Inc Moderate to Severe Plaque Psoriasis Medications Product
Table 109. UCB, Inc Recent Developments/Updates
Table 110. Dermavant Sciences Company Information
Table 111. Dermavant Sciences Description and Business Overview
Table 112. Dermavant Sciences Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Dermavant Sciences Moderate to Severe Plaque Psoriasis Medications Product
Table 114. Dermavant Sciences Recent Developments/Updates
Table 115. GSK Company Information
Table 116. GSK Description and Business Overview
Table 117. GSK Moderate to Severe Plaque Psoriasis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. GSK Moderate to Severe Plaque Psoriasis Medications Product
Table 119. GSK Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Moderate to Severe Plaque Psoriasis Medications Distributors List
Table 123. Moderate to Severe Plaque Psoriasis Medications Customers List
Table 124. Moderate to Severe Plaque Psoriasis Medications Market Trends
Table 125. Moderate to Severe Plaque Psoriasis Medications Market Drivers
Table 126. Moderate to Severe Plaque Psoriasis Medications Market Challenges
Table 127. Moderate to Severe Plaque Psoriasis Medications Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Product Picture of Moderate to Severe Plaque Psoriasis Medications
Figure 2. Global Moderate to Severe Plaque Psoriasis Medications Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Moderate to Severe Plaque Psoriasis Medications Market Share by Type: 2024 & 2031
Figure 4. Injection Product Picture
Figure 5. Oral Product Picture
Figure 6. Topical Cream Product Picture
Figure 7. Global Moderate to Severe Plaque Psoriasis Medications Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Moderate to Severe Plaque Psoriasis Medications Market Share by Application: 2024 & 2031
Figure 9. Hospital Clinic
Figure 10. Pharmacy
Figure 11. Online Shopping Mall
Figure 12. Global Moderate to Severe Plaque Psoriasis Medications Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Moderate to Severe Plaque Psoriasis Medications Market Size (2020-2031) & (US$ Million)
Figure 14. Global Moderate to Severe Plaque Psoriasis Medications Sales (2020-2031) & (K Units)
Figure 15. Global Moderate to Severe Plaque Psoriasis Medications Average Price (US$/Unit) & (2020-2031)
Figure 16. Moderate to Severe Plaque Psoriasis Medications Report Years Considered
Figure 17. Moderate to Severe Plaque Psoriasis Medications Sales Share by Manufacturers in 2024
Figure 18. Global Moderate to Severe Plaque Psoriasis Medications Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Moderate to Severe Plaque Psoriasis Medications Players: Market Share by Revenue in Moderate to Severe Plaque Psoriasis Medications in 2024
Figure 20. Moderate to Severe Plaque Psoriasis Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Moderate to Severe Plaque Psoriasis Medications Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country (2020-2031)
Figure 23. North America Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country (2020-2031)
Figure 24. United States Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country (2020-2031)
Figure 27. Europe Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country (2020-2031)
Figure 28. Germany Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Region (2020-2031)
Figure 35. China Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country (2020-2031)
Figure 43. Latin America Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country (2020-2031)
Figure 44. Mexico Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa Moderate to Severe Plaque Psoriasis Medications Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa Moderate to Severe Plaque Psoriasis Medications Revenue Market Share by Country (2020-2031)
Figure 49. Turkey Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE Moderate to Severe Plaque Psoriasis Medications Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of Moderate to Severe Plaque Psoriasis Medications by Type (2020-2031)
Figure 53. Global Revenue Market Share of Moderate to Severe Plaque Psoriasis Medications by Type (2020-2031)
Figure 54. Global Moderate to Severe Plaque Psoriasis Medications Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of Moderate to Severe Plaque Psoriasis Medications by Application (2020-2031)
Figure 56. Global Revenue Market Share of Moderate to Severe Plaque Psoriasis Medications by Application (2020-2031)
Figure 57. Global Moderate to Severe Plaque Psoriasis Medications Price (US$/Unit) by Application (2020-2031)
Figure 58. Moderate to Severe Plaque Psoriasis Medications Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
